SCHEMBL4533934

SCHEMBL4533934

O=C(Nc1ccncc1)c1n[nH]c2ccc(-c3cncc4c(NCc5ccccc5)cccc34)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.54
KDR P35968 2/20 0.54
ABL1 P00519 1/20 0.54
CSF1R P07333 1/20 0.54
IGF1R P08069 1/20 0.54
PDGFRB P09619 1/20 0.54
KIT P10721 1/20 0.54
FGFR1 P11362 1/20 0.54
FLT4 P35916 1/20 0.54
TEK Q02763 1/20 0.54
DYRK1A Q13627 15/20 0.50
WNT1 P04628 10/20 0.50
CLK2 P49760 3/20 0.48
CLK3 P49761 2/20 0.48
MAPK3 P27361 1/20 0.46
MAPK1 P28482 1/20 0.46
HAO1 Q9UJM8 1/20 0.46
CDK2 P24941 2/20 0.46
CCNA2 P20248 1/20 0.46
FLT3 P36888 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82655 0.82 DYRK1A (0.70) FLT1KDRABL1CSF1RIGF1R
SCHEMBL4523358 0.81 DYRK1A (0.58) FLT1KDRABL1CSF1RIGF1R
SCHEMBL4519185 0.80 DYRK1A (0.47) FLT1KDRABL1CSF1RIGF1R
SCHEMBL951209 0.77 DYRK1A (0.54) DYRK1AWNT1CLK2CLK3CDK2
SCHEMBL5716625 0.77 DYRK1A (0.56) DYRK1AWNT1CLK2CLK3CDK2
SCHEMBL4521537 0.76 FLT1 (0.44) FLT1KDRABL1CSF1RIGF1R
Hydrochloric Acid SCHEMBL4529550 0.76 DYRK1A (0.55) DYRK1AWNT1CLK2CLK3CDK2
Hydrochloric Acid SCHEMBL951130 0.76 DYRK1A (0.55) DYRK1AWNT1CLK2CLK3CDK2
SCHEMBL6221664 0.75 DYRK1A (0.68) DYRK1AWNT1CLK2CLK3
SCHEMBL23533901 0.75 DYRK1A (0.64) DYRK1AWNT1CLK2CLK3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482342-B2 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US disclosed
EP-1549620-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS Sanofi-Aventis (FR) 2005-07-06 EP disclosed
WO-2004031158-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS SANOFI-AVENTIS (FR) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors CDK2, CDK1, CDK4 FLT1 702/4885KDR 822/4885ABL1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.